Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc.

PBHNYSE / NASDAQHealthcareMid cap

$49.63+$0.03 (+0.1%)

Last close · Data as of Nov 20, 2026

Market cap
$2.2B
P/E
11.3x
EV / EBITDA
9.5x
Revenue
$1.1B
Net margin
17.5%
ROCE
9.2%

-16.1% over the last year

Prestige Consumer Healthcare Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+0.5%
3M
-1.8%
6M
+5.2%
1Y
-16.1%
5Y
-14.8%

52-week range

Day change +$0.03 (+0.1%) from $50 to $50 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in PBH, bought on each weekday since 2021.

News & filings

What Prestige Consumer Healthcare filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating margin of 28.4% against a peer median of 8.9%.

Concerns (1)

  • The P/E of 11.3 is 110% above the peer median of 5.4.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2026

Rule-based from financial data. Not advice.

About the company

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Read moreShow less

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under Debrox brand name. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Sector
Healthcare
Shares outstanding
48.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$2.2B
P/E
11.3x
P/B
1.1x
EV / EBITDA
9.5x
EV / Sales
2.9x
P/S
2.0x
52-week high
$70.21
52-week low
$42.98

Profitability

Operating margin
28.4%
Net margin
17.5%
EBITDA margin
30.4%
ROE
10.1%
ROCE
9.2%
ROA
5.4%
Asset turnover
0.31

Growth

Revenue
$1.1B
Revenue growth, 1Y
-4.3%
Revenue CAGR, 3Y
-1.2%
Net profit growth, 1Y
-11.3%
Free cash flow
$246.4M

Solvency

Current ratio
3.57
Debt / Equity
0.55
Debt / Assets
0.30
CFO / Net profit
1.35
Cash / Market cap
3.0%

Where the revenue went

Of every $100 of FY2026 revenue, $17 was left as net income.

Prestige Consumer Healthcare Inc. income statement flow, FY2026
Prestige Consumer Healthcare Inc. income statement flow, FY2026: flows
FromToAmount
RevenueCost of revenue$493.1M
RevenueGross profit$595.6M
Gross profitSelling, general and administrative$265.2M
Gross profitOther operating expenses$20.9M
Gross profitOperating income$309.4M
Operating incomePretax income$257.5M
Operating incomeInterest and other expense$51.9M
Pretax incomeTax and other$67.2M
Pretax incomeNet income$190.3M

Revenue and net profit

Revenue fell 4.3% in FY2026; net profit is the dashed line.

Prestige Consumer Healthcare Inc. revenue and net profit by fiscal year
Prestige Consumer Healthcare Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2023$1.1B-$82.3M
FY2024$1.1B$209.3M
FY2025$1.1B$214.6M
FY2026$1.1B$190.3M

Cash flows

FY2026: $257.6M from operations, $246.4M free after investment (dashed).

Prestige Consumer Healthcare Inc. operating and free cash flow by fiscal year
Prestige Consumer Healthcare Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2023$229.7M$221.9M
FY2024$248.9M$239.4M
FY2025$251.5M$243.3M
FY2026$257.6M$246.4M

Growth

Latest fiscal year 2026: each figure with its change over the year before.

Revenue
$1.1B-4.3%1Y
EBITDA
$331.1M-8.5%1Y
Net profit
$190.3M-11.3%1Y
Cash from operations
$257.6M+2.4%1Y
Free cash flow
$246.4M+1.3%1Y
Revenue CAGR, 3Y
-1.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2026$1.1B$331.1M$190.3M$246.4M10.1%-4.3%-11.3%

Monthly returns

Month-by-month returns of PBH across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2026.

LineFY2026
Assets$3.5B
Liabilities$1.6B
Equity$1.9B
Paid-in capital$608.5M
Retained earnings$1.7B
Treasury stock$439.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; PBH highlighted.

P/E against peers

PBH trades at 11.3x earnings against a peer median of 5.4x (a 110% premium).

  1. Prestige Consumer Healthcare Inc. (this company)11.3x

Not shown (no positive earnings and no EV / Sales): Supernus Pharmaceuticals, Inc., Acadia Healthcare Company, Inc., Neogen Corporation, Sarepta Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Prestige Consumer Healthcare Inc.PBHthis companyP/E ↑ premium$2.2B11.3x1.1x10.1%9.5x
Supernus Pharmaceuticals, Inc.SUPN$2.6B-67.3x2.4x-3.6%58.9x
TransMedics Group, Inc.TMDX$2.5B13.0x5.2x40.2%16.8x
Acadia Healthcare Company, Inc.ACHC$2.3B-2.1x1.2x-56.6%-6.5x
LeMaitre Vascular, Inc.LMAT$2.1B37.0x5.4x14.7%25.3x
Select Medical Holdings CorporationSEM$2.0B14.0x1.2x8.6%9.2x
Neogen CorporationNEOG$2.0B-1.8x1.0x-52.7%-2.9x
ADMA Biologics, Inc.ADMA$1.8B12.6x3.9x30.8%9.3x
Sarepta Therapeutics, Inc.SRPT$1.8B-2.5x1.5x-62.5%-3.2x
Peer median—5.4x2.0x2.5%9.3x

Year-to-date ROI

PBH since 1 January, against earlier years.

Historical volatility

PBH's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Prestige Consumer Healthcare Inc. operating margin by fiscal year
Prestige Consumer Healthcare Inc. operating margin by fiscal year
DateOperating margin
FY202330.8%
FY202430.4%
FY202530.7%
FY202628.4%
LineFY2026
Cost of revenueCost Of Revenue$493.1M
Gross profitGross Profit$595.6M
Operating expensesOperating Expense$286.2M
Depreciation and amortisationDepreciation And Amortization In Income Statement$20.9M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$20.9M
Total expensesTotal Expenses$779.3M
Pretax incomePretax Income$257.5M

Learn while you research

Academy chapters picked for Prestige Consumer Healthcare Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 11.3 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →